Endocrine treatment of advanced breast cancer.
Endocrine treatment is the preferred first-line therapy for advanced breast cancer because of its good tolerability. There are several groups of agents which differ in their mode of action but almost all in some way reduce stimulation by oestrogen. Over recent years, there has been a substantial increase in the number of medical agents in clinical trial. New antioestrogens with reduced or no agonist activity, and potent, more specific, aromatase inhibitors are now reaching the clinic. In most cases, the clinical effectiveness of these agents remains to be fully established and their optimal therapeutic application is yet to be determined.
Dowsett
M
M
Royal Marsden Hospital, London, England.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D045167:Progesterone Congeners / Q000627:therapeutic use; D011372:Progestins / Q000037:antagonists & inhibitors
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D045167:Progesterone Congeners; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone